TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bachem Holding AG ( (CH:BANB) ) has issued an announcement.
Bachem Holding AG has reached a significant milestone in its capacity expansion plans with the inspection of Building K at its Bubendorf site, ensuring no delays in its development timeline. Additionally, the acquisition of property adjacent to its Vista, California site will bolster its production capabilities in the US, with plans to invest around USD 250 million from 2026 to 2030, enhancing its position in the global healthcare market.
The most recent analyst rating on (CH:BANB) stock is a Hold with a CHF61.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.
More about Bachem Holding AG
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. It offers a comprehensive range of services to pharmaceutical and biotechnology companies worldwide for research, clinical development, and commercial application. With its headquarters in Switzerland and operations in Europe, the USA, and Asia, Bachem has over 50 years of experience and is listed on the SIX Swiss Exchange.
Average Trading Volume: 109,254
Technical Sentiment Signal: Strong Sell
Current Market Cap: CHF4.12B
For detailed information about BANB stock, go to TipRanks’ Stock Analysis page.